Drugs / Soybean oil lipid emulsion
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02512718 Comparator | Jun 2016 → May 2023 | disease related to hematopoietic stem cell transplant | Alexandra N. Carey | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Soybean oil lipid emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02512718 ↗ |
| Known as | SOLE | “Soybean oil lipid emulsion (SOLE) is the standard lipid emulsion used in PN.” NCT02512718 ↗ |
| Modality | Other / unclassified | “Soybean oil lipid emulsion (SOLE) is the standard lipid emulsion used in PN.” NCT02512718 ↗ |
| Route | Intravenous | “1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily” NCT02512718 ↗ |